Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

No abstract is available for this paper.

• Publication year

  1977

• Venue

  The Lancet

• Publication date

  1977-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(77)91940-7PMID 65560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Research Methods in Neurochemistry

  2013cited by this paper
• Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths

  2005cited by this paper
• Physiological and pathological changes in tissue monoamine oxidase activity

  2005cited by this paper
• The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

  2005cited by this paper
• Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings)

  2005cited by this paper
• Study of deterioration in long-term treatment of parkinsonism with L-Dopa plus decarboxylase inhibitor

  2005cited by this paper
• Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase

  2005cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• Multiple forms of monoamine oxidase: Fact and artefact

  1976cited by this paper
• Time course of nigrostriatal degeneration in parkinson's disease

  1976cited by this paper
• Interaction of β‐phenethylamine with dopamine and noradrenaline in the central nervous system of the rat

  1976cited by this paper
• Interaction of beta-phenethylamine with dopamine and noradrenaline in the central nervous system of the rat.

  1976cited by this paper
• Some properties of human platelet monoamine oxidase in iron-deficiency anaemia.

  1976cited by this paper
• MONOAMINE OXIDASE AND ITS INHIBITION

  1976cited by this paper
• Multiple forms of monoamine oxidase: fact and artefact.

  1976cited by this paper
• EFFECTS OF MONOAMINE OXIDASE INHIBITION BY CLORGYLINE, DEPRENIL OR TRANYLCYPROMINE ON 5‐HYDROXYTRYPTAMINE CONCENTRATIONS IN RAT BRAIN AND HYPERACTIVITY FOLLOWING SUBSEQUENT TRYPTOPHAN ADMINISTRATION

  1975cited by this paper
• THE SUBCELLULAR DISTRIBUTION OF β‐PHENYLETHYLAMINE, p‐TYRAMINE AND TRYPTAMINE IN RAT BRAIN

  1975cited by this paper
• The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.

  1975cited by this paper
• Some arylalkylamines in rabbit brain.

  1975cited by this paper
• Monoamine oxidase in man: enzyme characteristics in platelets, plasma, and other human tissues.

  1974cited by this paper
• The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines.

  1974cited by this paper
• Effect of chronic l‐DOPA administration on catecholamine metabolism in the rat

  1973cited by this paper
• Structure‐activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopaminergic neurones in rat brain homogenates

  1973cited by this paper
• Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

  1973cited by this paper
• Tetrahydroisoquinoline Alkaloids: in vivo Metabolites of L-Dopa in Man

  1973cited by this paper
• Isolation and characterization of phenylethylamine and phenylethanolamine from human brain

  1973cited by this paper
• Effects of levodopa on nondopaminergic brain neurons

  1972cited by this paper
• Phenethylamine content of human urine and rat brain, its alterations in pathological conditions and after drug administration

  1972cited by this paper
• Reduced Monoamine Oxidase Activity in Blood Platelets from Schizophrenic Patients

  1972cited by this paper
• A comparison of the pharmacological and biochemical properties of substrate‐selective monoamine oxidase inhibitors

  1972cited by this paper
• [Modern treatment of parkinsonism].

  1972cited by this paper
• Some puzzling pharmacological effects of monoamine oxidase inhibitors.

  1972cited by this paper
• Levodopa in the treatment of Parkinsonism.

  1971cited by this paper
• On the mode of action of L-dopa in Parkinson's disease.

  1970cited by this paper
• [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)].

  1967cited by this paper
• Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

  1965cited by this paper
• FORMATION OF β-PHENYLETHYLAMINE IN MAMMALIAN TISSUE AND ITS EFFECT ON MOTOR ACTIVITY IN THE MOUSE

  1964cited by this paper
• URINARY EXCRETION OF PHENETHYLAMINE AND TYRAMINE IN NORMAL SUBJECTS AND HETEROZYGOUS CARRIERS OF PHENYLKETONURIA.

  1964cited by this paper
• Dopamine and basal ganglia diseases.

  1961cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review

  2025cites this paper
• Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions

  2023cites this paper
• L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin

  2023cites this paper
• Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline

  2023cites this paper
• Recent Advances in Drug Therapy for Parkinson's Disease

  2022cites this paper
• Treatment; Moussa B.H. Youdim

  2022cites this paper
• Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson’s disease

  2022cites this paper
• Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease

  2021cites this paper
• Pathogenic Factors and Treatment of Parkinson’s Disease

  2021cites this paper
• Role of Oxidative Stress in the Etiology of Parkinson’s Disease: Advanced Therapeutic Products

  2021cites this paper
• Synergistic effects of curcumin and its analogs with other bioactive compounds: A comprehensive review.

  2020cites this paper
• The discovery and development of rasagiline as a new anti-Parkinson medication

  2020cites this paper
• Nanomedicine against Alzheimer's and Parkinson's disease.

  2020cites this paper
• Article 4

  2020cites this paper
• A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.

  2020cites this paper
• Selegiline: a molecule with innovative potential

  2019cites this paper
• Dance experience predicts improvement from movement therapy in Parkinson's disease

  2019cites this paper
• Fabrication and evaluation of selegiline HCl embedded transdermal film for management of Parkinson’s disease

  2019cites this paper
• Selegiline ameliorates depression‐like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity

  2019cites this paper
• The role of nitric oxide—cGMP pathway in selegiline antidepressant-like effect in the mice forced swim test

  2018cites this paper
• Parkinson's disease: A review

  2018cites this paper
• An investigation of indanone derivatives as inhibitors of monoamine oxidase

  2018cites this paper
• Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases

  2018cites this paper
• Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors.

  2018cites this paper
• Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease

  2018cites this paper
• Chapter 9 Nrf 2 and Parkinson ’ s Disease

  2018cites this paper
• World's Technology Medicine Open Access book

  2017cites this paper
• Effects on Sperms’ Quality of Selegiline in Aged Rats

  2017cites this paper
• Disease Primers PARKINSON DISEASE

  2017cites this paper
• Evaluation of selected dye compounds as inhibitors of monoamine oxidase

  2017cites this paper
• Parkinson disease

  2017cites this paper
• Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson’s Disease

  2017cites this paper
• The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015)

  2016cites this paper
• Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).

  2016cites this paper
• Nrf2: a modulator of Parkinson’s disease?

  2016cites this paper
• THE DISCOVERY OF THE ENHANCER REGULATION IN THE MAMMALIAN BRAIN AND THE DEVELOPMENT OF THE SYNTHETIC ENHANCER SUBSTANCES A chance to significantly improve the quality and prolong the duration of human life

  2016cites this paper
• OMICS as Therapeutic Platform: Environmental Factors to Parkinson's Disease

  2016cites this paper
• Nrf2 and Parkinson’s Disease

  2016cites this paper
• Neuroprotective Effect of the Marine-Derived Compound 11-Dehydrosinulariolide through DJ-1-Related Pathway in In Vitro and In Vivo Models of Parkinson’s Disease

  2016cites this paper
• Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

  2016cites this paper
• Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

  2016cites this paper
• 4 – Approches pharmacologique et physiopathologique de la dépression majeure : un aller-retour paradigmatique

  2015cites this paper
• Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.

  2014cites this paper
• Essential difference between the pharmacological spectrum of (−)-deprenyl and rasagiline

  2014cites this paper
• Flavins and flavoproteins: applications in medicine.

  2014cites this paper
• Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.

  2014cites this paper
• Alkaloids as Inhibitors of Monoamine Oxidases and Their Role in the Central Nervous System

  2014cites this paper
• Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.

  2014cites this paper
• [Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].

  2014cites this paper
• Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies

  2013cites this paper
• Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline

  2013cites this paper
• The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease

  2013cites this paper
• How Selegiline ((-)-Deprenyl) Slows Brain Aging

  2012cites this paper
• Selective serotonin reuptake inhibitors and tricyclic antidepressants : novel immunomodulating agents

  2012cites this paper
• Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes

  2012cites this paper
• Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives.

  2012cites this paper
• Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk.

  2011cites this paper
• The pharmacology of selegiline.

  2011cites this paper
• Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.

  2011cites this paper
• Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.

  2011cites this paper
• The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model

  2011cites this paper
• Neuroprotective effects of amantadine–flavonoid conjugates

  2011cites this paper
• MAO-inhibitors in Parkinson's Disease

  2011cites this paper
• Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease

  2011cites this paper
• The Knoll-Concept to Decrease the Prevalence of Parkinson’s Disease

  2011cites this paper
• IN-VITRO STUDY OF THE EFFECTS OF ETHANOLIC EXTRACT OF LONCHOCARPUS CYANESCENS AND CRASSOCEPHALUM CREPIDIOIDES LEAF EXTRACTS ON MONOAMINE OXIDASE ACTIVITY FROM RAT BRAIN

  2010cites this paper
• [Rasagiline: effectiveness and protection in Parkinson's disease].

  2010cites this paper
• Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

  2010influential citation
• Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.

  2010cites this paper
• Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential

  2010cites this paper
• R-Deprenyl: Pharmacological Spectrum of its Activity

  2010cites this paper
• Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities

  2010cites this paper
• Newdrugdeliverystrategies forimprovedParkinson'sdisease therapy

  2009cites this paper
• Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain

  2009cites this paper
• New drug delivery strategies for improved Parkinson's disease therapy

  2009cites this paper
• New drug delivery strategies for improved Parkinson's disease therapy.

  2009cites this paper
• Progress in Parkinson's disease-where do we stand?

  2008cites this paper
• [Parkinson disease. The clinical picture and therapy].

  2008cites this paper
• Characterization of a novel interaction between presenilin-1 and monoamine oxidase-A

  2008cites this paper
• Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants

  2008cites this paper
• Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.

  2007cites this paper
• Monoamine oxidase A and B inhibitors in Parkinson's disease.

  2007cites this paper
• The meeting of minds and times with Peter Riederer: an appreciation

  2007cites this paper
• Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil

  2006cites this paper
• The therapeutic potential of monoamine oxidase inhibitors

  2006cites this paper
• Deprenyl: from chemical synthesis to neuroprotection.

  2006cites this paper
• Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.

  2006cites this paper
• Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum.

  2006cites this paper
• Experiences with L-deprenyl in Parkinsonism

  2005cites this paper
• The active centers of monoamine oxidase types “A” and “B”: Binding with (14C)-clorgyline and (14C)-deprenyl

  2005cites this paper
• The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients

  2005cites this paper
• Absence of “cheese effect” during deprenyl therapy: Some recent studies

  2005cites this paper
• Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO “type B” inhibitor

  2005cites this paper
• Effects of L-deprenyl on human growth hormone secretion

  2005cites this paper
• Recent observations on the clinical pharmacology of (-)deprenyl

  2005cites this paper
• Long term treatment with L-deprenyl

  2005cites this paper
• L-deprenyl treatment of on-off phenomena in Parkinson's disease

  2005cites this paper
• Antidepressant-like effects of selegiline in the forced swim test.

  2005cites this paper
• Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

  2005cites this paper
• Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.

  2005cites this paper